Expression of proteins involved in DNA damage response in familial and sporadic breast cancer patients

International Journal of Cancer

Volumn 138, Issue 1, 2016, Pages 110-120

  Partipilo, Giulia ^a   Simone, Giovanni ^a   Scattone, Anna ^a   Scarpi, Emanuela ^b   Azzariti, Amalia ^a   Mangia, Anita ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

BRCA1; BRIT1; immunohistochemistry; PARP1; sporadic and familial breast cancers

Indexed keywords

BRCA1 PROTEIN; BRCT REPEAT INHIBITOR OF HTERT EXPRESSION; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; REGULATOR PROTEIN; SWITCH 5 PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; BREAST TUMOR; CANCER STAGING; DNA DAMAGE; FEMALE; GENE EXPRESSION; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; DNA DAMAGE; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; YOUNG ADULT;

EID: 84944275238     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29699     Document Type: Article

References (50)

1. Bray F, Ren JS, Masuyer E, et al., Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013; 132: 1133-45.
2. Rice JC, Ozcelik H, Maxeiner P, et al., Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 2000; 21: 1761-5.
3. Ralhan R, Kaur J, Kreienberg R, et al., Links between DNA double strand break repair and breast cancer: Accumulating evidence from both familial and nonfamilial cases. Cancer Lett 2007; 248: 1-17.
4. Broustas CG, Lieberman HB., DNA damage response genes and the development of cancer metastasis. Radiat Res 2014; 181: 111-30.
5. Mavaddat N, Antoniou AC, Easton DF, et al., Genetic susceptibility to breast cancer. Mol Oncol 2010; 4: 174-91.
6. Deng CX., BRCA1: Cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res 2006; 34: 1416-26.
7. Levin B, Lech D, Friedenson B., Evidence that BRCA1- or BRCA2-associated cancers are not inevitable. Mol Med 2012; 18: 1327-37.
8. Amé JC, Spenlehauer C, de Murcia G., The PARP superfamily. Bioessays 2004; 26: 882-93.
9. Ossovskaya V, Koo IC, Kaldjian EP, et al., Upregulation of poly (ADP-ribose) polymerase-1 (PARP1) in triple-negative breast cancer and other primary human tumor types. Genes Cancer 2010; 1: 812-21.
10. Bieche I, Pennaneach V, Driouch K, et al., Variations in the mRNA expression of poly(ADP-ribose) polymerases, poly(ADP-ribose) glycohydrolase and ADP-ribosylhydrolase 3 in breast tumors and impact on clinical outcome. Int J Cancer 2013; 133: 2791-800.
11. Domagala P, Huzarski T, Lubinski J, et al., PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: Possible implications for PARP-1 inhibitor therapy. Breast Cancer Res Treat 2011; 127: 861-9.
12. Gonçalves A, Finetti P, Sabatier R, et al., Poly (ADP-ribose) polymerase-1 mRNA expression in human breast cancer: A meta-analysis. Breast Cancer Res Treat 2011; 127: 273-81.
13. Rojo F, García-Parra J, Zazo S, et al., Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. Ann Oncol 2012; 23: 1156-64.
14. Sulzyc-Bielicka V, Domagala P, Hybiak J, et al., Colorectal cancers differ in respect of PARP-1 protein expression. Pol J Pathol 2012; 63: 87-92.
15. Klauschen F, von Winterfeld M, Stenzinger A, et al., High nuclear poly-(ADP-ribose)-polymerase expression is prognostic of improved survival in pancreatic cancer. Histopathology 2012; 61: 409-16.
16. Salemi M, Galia A, Fraggetta F, et al., Poly (ADP-ribose) polymerase 1 protein expression in normal and neoplastic prostatic tissue. Eur J Histochem 2013; 57: E13.
17. Lee JM, Ledermann JA, Kohn EC., PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol 2014; 25: 32-40.
18. Sonnenblick A, de Azambuja E, Azim HA, Jr, et al., An update on PARP inhibitors-moving to the adjuvant setting. Nat Rev Clin Oncol 2015; 12: 27-41.
19. Lin SY, Elledge SJ., Multiple tumor suppressor pathways negatively regulate telomerase. Cell 2003; 113: 881-9.
20. Xu X, Lee J, Stern DF., Microcephalin is a DNA damage response protein involved in regulation of CHK1 and BRCA1. J Biol Chem 2004; 279: 34091-4.
21. Rai R, Dai H, Multani AS, et al., BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell 2006; 10: 145-57.
22. Yang SZ, Lin FT, Lin WC., MCPH1/BRIT1 cooperates with E2F1 in the activation of checkpoint, DNA repair and apoptosis. EMBO Rep 2008; 9: 907-15.
23. Neely KE, Hassan AH, Brown CE, et al., Transcription activator interactions with multiple SWI/SNF subunits. Mol Cell Biol 2002; 22: 1615-25.
24. Akamatsu Y, Tsutsui Y, Morishita T, et al., Fission yeast Swi5/Sfr1 and Rhp55/Rhp57 differentially regulate Rhp51-dependent recombination outcomes. EMBO J 2007; 26: 1352-62.
25. Akamatsu Y, Jasin M., Role for the mammalian Swi5-Sfr1 complex in DNA strand break repair through homologous recombination. PLoS Genet 2010; 6: E1001160.
26. Yuan J, Chen J., The role of the human SWI5-MEI5 complex in homologous recombination repair. J Biol Chem 2011; 286: 9888-93.
27. Fornander LH, Renodon-Cornière A, Kuwabara N, et al., Swi5-Sfr1 protein stimulates Rad51-mediated DNA strand exchange reaction through organization of DNA bases in the presynaptic filament. Nucleic Acids Res 2014; 42: 2358-65.
28. Bochar DA, Wang L, Beniya H, et al., BRCA1 is associated with a human SWI/SNF-related complex: Linking chromatin remodeling to breast cancer. Cell 2000; 102: 257-65.
29. Peng G, Yim EK, Dai H, et al., BRIT1/MCPH1 links chromatin remodelling to DNA damage response. Nat Cell Biol 2009; 11: 865-72.
30. + exchanger regulatory factor 1, and breast cancer susceptibility gene-1 as new biomarkers for familial breast cancers. Hum Pathol 2011; 42: 1589-95.
31. Wolff AC, Hammond ME, Schwartz JN, et al., American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131: 18-43.
32. Green AR, Caracappa D, Benhasouna AA, et al., Biological and clinical significance of PARP1 protein expression in breast cancer. Breast Cancer Res Treat 2015; 149: 353-62.
33. De Summa S, Pinto R, Pilato B, et al., Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer. Cell Death Dis 2014; 5: E1076.
34. Ghabreau L, Roux JP, Frappart PO, et al., Poly(ADP-ribose) polymerase-1, a novel partner of progesterone receptors in endometrial cancer and its precursors. Int J Cancer 2004; 109: 317-21.
35. Thompson ME., BRCA1 16 years later: Nuclear import and export processes. FEBS J 2010; 277: 3072-8.
36. Milner R, Wombwell H, Eckersley S, et al., Validation of the BRCA1 antibody MS110 and the utility of BRCA1 as a patient selection biomarker in immunohistochemical analysis of breast and ovarian tumours. Virchows Arch 2013; 462: 269-79.
37. Rakha EA, El-Sheikh SE, Kandil MA, et al., Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum Pathol 2008; 39: 857-65.
38. Mylona E, Melissaris S, Nomikos A, et al., Effect of BRCA1 immunohistochemical localizations on prognosis of patients with sporadic breast carcinomas. Pathol Res Pract 2014; 210: 533-40.
39. Mangia A, Chiriatti A, Tommasi S, et al., BRCA1 expression and molecular alterations in familial breast cancer. Histol Histopathol 2009; 24: 69-76.
40. Fraser JA, Reeves JR, Stanton PD, et al., A role for BRCA1 in sporadic breast cancer. Br J Cancer 2003; 88: 1263-70.
41. Turner NC, Reis-Filho JS, Russell AM, et al., BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007; 26: 2126-32.
42. Lee WY, Jin YT, Chang TW, et al., Immunolocalization of BRCA1 protein in normal breast tissue and sporadic invasive ductal carcinomas: A correlation with other biological parameters. Histopathology 1999; 34: 106-12.
43. Lambie H, Miremadi A, Pinder SE, et al., Prognostic significance of BRCA1 expression in sporadic breast carcinomas. J Pathol 2003; 200: 207-13.
44. Jarvis EM, Kirk JA, Clarke CL., Loss of nuclear BRCA1 expression in breast cancers is associated with a highly proliferative tumor phenotype. Cancer Genet Cytogenet 1998; 101: 109-15.
45. Yoshikawa K, Honda K, Inamoto T, et al., Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases. Clin Cancer Res 1999; 5: 1249-61.
46. Richardson J, Shaaban AM, Kamal M, et al., Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation. Breast Cancer Res Treat 2011; 127: 639-48.
47. Jo YH, Kim HO, Lee J, et al., MCPH1 protein expression and polymorphisms are associated with risk of breast cancer. Gene 2013; 517: 184-90.
48. Wysham WZ, Mhawech-Fauceglia P, Li H, et al., BRCAness profile of sporadic ovarian cancer predicts disease recurrence. PLoS One 2012; 7: E30042.
49. Farmer H, McCabe N, Lord CJ, et al., Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21.
50. Pan MR, Hsieh HJ, Dai H, et al., Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair, and its deficiency sensitizes cells to poly(ADP-ribose) polymerase (PARP) inhibitor treatment. J Biol Chem 2012; 287: 6764-72.